Find information on thousands of medical conditions and prescription drugs.

Casodex

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease.

It is marketed by AstraZeneca with the brand names Casodex and Cosudex. Bicalutamide is recommended 50 mg once daily in combination with an LHRH analogue or surgical castration for the treatment of advanced prostrate cancer

A

B

C

Calcium folinate

Chenodeoxycholic acid

Chloramphenicol

Chlordiazepoxide

Chlorprothixene

Chlortetracycline

Choriogonadotropin alfa

Chorionic gonadotropin

Clavulanic acid

Cyclobenzaprine

Cyclophosphamide

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]



	Mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma Abstract Chemotherapeutic agents may induce a wide variety of adverse mucocutaneous effects, including nail changes. We present a case of atypical ... From Journal of Drugs in Dermatology, 7/1/05 by Anatoli Freiman

	Research and Markets: Astrazeneca Promoting Casodex Monotherapy Heavily In Non-Metastatic Disease As An Alternative To An Lhrh Agonist DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c8001) has announced the addition of Prostate Cancer Insight - Profiting ... From Business Wire, 10/25/04

	Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene - Research Hexachlorobenzene (HCB) is a persistent environmental contaminant that has the potential to interfere with steroid hormone regulation. The prostate requires precise control by androgens to regulate From Environmental Health Perspectives, 4/1/03 by Jody L. Ralph

	"My prostate cancer's back. Now what?" Learn how to help your patient explore his treatment options. Your patient has questions. Having undergone external beam radiation therapy as primary ... From Nursing, 4/1/02 by Jackson, Rene A

	Interaction Of Vitamin D With Androgen In Prostate Cancer The purpose of this (Stanford University) research is to gain an understanding of the vitamin D-androgen interaction in prostate cancer. Calcitriol, ... From Life Sciences & Biotechnology Update, 2/1/01

	Safety of RU-486 Is Questionable The FDA's accelerated approval of the abortion-inducing drug RU-486 without thorough testing is under fire by critics of the drug who say the FDA broke ... From Insight on the News, 1/29/01 by Stephanie K. Taylor

	Zeneca's growth prescription - interview with Zeneca CEO David Barnes - Interview Zeneca CEO Sir David Barnes believes that the recent increase in his company's market value is only the beginning rather than the peak of its strong performance. From Chief Executive, The, 4/1/98 by J.P. Donlon

	Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature A 69-year-old man with advanced prostate cancer was receiving antiandrogen therapy (bicalutamide [Casodex]). He developed dyspnea, peripheral eosinophilia ... From CHEST, 2/1/98 by Philip W. Wong

Home

Contact

Resources

ebay